US FDA plans expanded conflict-of-interest disclosures for advisory panels
This article was originally published in RAJ Devices
Executive Summary
The US Food and Drug Administration has proposed new conflict-of-interest waiver guidelines that would publicly identify the companies or institutions at issue when an advisory panel member has a financial conflict1,2.